Adverum Biotechnologies (STU:AVU0) Beginning Cash Position : €70.82 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Beginning Cash Position?

Adverum Biotechnologies's Beginning Cash Position for the quarter that ended in Mar. 2024 was €70.82 Mil.

Adverum Biotechnologies's quarterly Beginning Cash Position declined from Sep. 2023 (€106.66 Mil) to Dec. 2023 (€99.05 Mil) and declined from Dec. 2023 (€99.05 Mil) to Mar. 2024 (€70.82 Mil).

Adverum Biotechnologies's annual Beginning Cash Position declined from Dec. 2021 (€56.13 Mil) to Dec. 2022 (€34.64 Mil) but then increased from Dec. 2022 (€34.64 Mil) to Dec. 2023 (€65.05 Mil).

Adverum Biotechnologies Beginning Cash Position Historical Data

The historical data trend for Adverum Biotechnologies's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Beginning Cash Position Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

140.35

54.99

56.13

34.64

65.05

Adverum Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															66.25	64.66	106.66	99.05	70.82

Adverum Biotechnologies Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Adverum Biotechnologies Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (STU:AVU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines